Statistical Assessment of Biosimilarity Based on the Relative Distance Between Follow-on Biologics for Time-to-Event Endpoints

References

• Andersen, P. K., Hansen, M. G., and Klein, J. P. (2004), “Regression Analysis of Restricted Mean Survival Time Based on Pseudo-Observations,” Lifetime Data Analysis, 10, 335–350. DOI: 10.1007/s10985-004-4771-0.
   PubMed Web of Science ®Google Scholar
• Barker, K. B., Menon, S. M., D’Agostino Sr, R. B., Xu, and Jin, B. (2016), Biosimilar Clinical Development: Scientific Considerations and New Methodologies, Boca Raton, FL: CRC Press.
   Google Scholar
• Bender, R., Augustin, T., and Blettner, M. (2005), “Generating Survival Times to Simulate Cox Proportional Hazards Models,” Statistics in Medicine, 24, 1713–1723. DOI: 10.1002/sim.2059.
   PubMed Web of Science ®Google Scholar
• Chang, V. (2017), “Multi-regional Planning With Biosimilar Studies,” Presented in the 5th Internal Society of Biopharmaceutical Statistics.
   Google Scholar
• Chen, C. T., Tsou, H. H., Hsiao, C. F., Lai, Y. H., Chang, W. J., and Liu, J. T. (2017), “A Tolerance Interval Approach to Assessing the Biosimilarity of Follow-on Biologics,” Statistics in Biopharmaceutical Research, 9, 286–292. DOI: 10.1080/19466315.2017.1323669.
   Web of Science ®Google Scholar
• Chow, S. C. (2013), Biosimilars: Design and Analysis of Follow-on Biologics, Boac Raton, FL: Chapman and Hall/CRC.
   Google Scholar
• Chow, S. C., Wang, H., and Shao, J. (2007), Sample Size Calculations in Clinical Research, Boca Raton, FL: CRC Press.
   Google Scholar
• Combest, A. J., Wang, S., Healey, B. T., and Reitsma, D. J. (2014), “Alternative Statistical Strategies for Biosimilar Drug Development,” GaBI Journal, 3, 13–20. DOI: 10.5639/gabij.2014.0301.006.
   Google Scholar
• Cox, D. R. (1972), “Regression Models and Life-Tables,” Journal of the Royal Statistical Society, Series B, 34, 187–202. DOI: 10.1111/j.2517-6161.1972.tb00899.x.
   Web of Science ®Google Scholar
• EMA (2015), “Guideline on Similar Biological Medicinal Products,” European Medicines Agency, available at https://www.ema.europa.eu/en/similar-biological-medicinal-products.
   Google Scholar
• FDA (2015), “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product,” U.S. Food and Drug Administration, available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.
   Google Scholar
• Kang, S. H., and Chow, S. C. (2013), “Statistical Assessment of Biosimilarity Based on Relative Distance Between Follow-on Biologics,” Statistics in Medicine, 32, 382–392. DOI: 10.1002/sim.5582.
   PubMed Web of Science ®Google Scholar
• Harrell Jr, F. E. (1986) “The PHGLM Procedure. SUGI Supplemental Library User’s Guide,” SAS (Statistical Analysis System) Institute Inc., Version 5.
   Google Scholar
• Kaur, P., Chow, V., Zhang, N., Moxness, M., Kaliyaperumal, A., and Markus, R. (2017), “A Randomised, Single-Blind, Single-Dose, Three-Arm, Parallel-Group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of ABP 501 and Adalimumab,” Annals of the Rheumatic Diseases, 76, 526–533. DOI: 10.1136/annrheumdis-2015-208914.
   PubMed Web of Science ®Google Scholar
• Lachin, J. M., and Foulkes, M. A. (1986), “Evaluation of Sample Size and Power for Analyses of Survival With Allowance for Nonuniform Patient Entry, Losses to Follow-up, Noncompliance, and Stratification,” Biometrics, 42, 507–519. DOI: 10.2307/2531201.
   PubMed Web of Science ®Google Scholar
• Li, J. D., and Xu, J. (2016), “Bridging a New Biological Product With Its Reference Product,” in Biosimilar Clinical Development: Scientific Considerations and New Methodologies, eds. K. B., Barker, S.M., Menon, R.B., D’Agostino Sr, S. Xu, and B. Jin. Boca Raton, FL: Chapman and Hall/CRC, pp. 117–134.
   Google Scholar
• Liang, K. Y., and Zeger, S. L. (1986), “Longitudinal Data Analysis Using Generalized Linear Models,” Biometrika, 73, 13–22. DOI: 10.1093/biomet/73.1.13.
   Web of Science ®Google Scholar
• Luo, J., and Su, Z. (2013), “A Note on Variance Estimation in the Cox Proportional Hazards Model,” Journal of Applied Statistics, 40, 1132–1139. DOI: 10.1080/02664763.2013.780161.
   Web of Science ®Google Scholar
• Mielke, J., Jilma, B., Jones, B., and Koenig, F. (2018), “An Update on the Clinical Evidence That Supports Biosimilar Approvals in Europe,” British Journal of Clinical Pharmacology, 84, 1415–1431. DOI: 10.1111/bcp.13586.
   PubMed Web of Science ®Google Scholar
• Pan, H., Yuan, Y., and Xia, J. (2017), “A Calibrated Power Prior Approach to Borrow Information From Historical Data With Application to Biosimilar Clinical Trials,” Journal of the Royal Statistical Society, Series C, 66, 979–996. DOI: 10.1111/rssc.12204.
   Web of Science ®Google Scholar
• Park, J., and Kang, S. H. (2019), “The Determination of Biosimilarity Margin and the Assessment of Biosimilarity for an (m + 1)-Arm Parallel Design,” Communication in Statistics—Theory and Methods, accepted subject to minor revision.
   Google Scholar
• Royston, P., and Parmar, M. K. (2013), “Restricted Mean Survival Time: An Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials With a Time-to-Event Outcome,” BMC Medical Research Methodology, 13, 152. DOI: 10.1186/1471-2288-13-152.
   PubMed Web of Science ®Google Scholar
• Sashegyi, A., and Ferry, D. (2017), “On the Interpretation of the Hazard Ratio and Communication of Survival Benefit,” The Oncologist, 22, 484–486. DOI: 10.1634/theoncologist.2016-0198.
   PubMed Web of Science ®Google Scholar
• Sedgwick, P., and Joekes, K. (2015), “Interpreting Hazard Ratios,” BMJ, 351, h4631. DOI: 10.1136/bmj.h4631.
   PubMedGoogle Scholar
• Shin, W., and Kang, S. H. (2016), “Statistical Assessment of Biosimilarity Based on the Relative Distance Between Follow-on Biologics for Binary Endpoints,” Journal of Biopharmaceutical Statistics, 26, 227–239. DOI: 10.1080/10543406.2014.979195.
   PubMed Web of Science ®Google Scholar
• Therneau, T. M., and Grambsch, P. M. (2013), Modeling Survival Data: Extending the Cox Model, New York: Springer.
   Google Scholar
• Uno, H., Schrag, D., Kim, D. H., Tang, D., Tian, L., Rugo, H. S., and Wei, L. J. (2019), “Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes,” JNCI Cancer Spectrum, 3, pkz058. DOI: 10.1093/jncics/pkz058.
   PubMed Web of Science ®Google Scholar
• Uno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., and Wei, L. J. (2015), “Alternatives to Hazard Ratios for Comparing Efficacy or Safety of Therapies in Noninferiority Studies,” Annals of Internal Medicine, 163, 127. DOI: 10.7326/M14-1741.
   PubMed Web of Science ®Google Scholar
• Webster, C. J., and Woollett, G. R. (2017), “A ‘Global Reference’ Comparator for Biosimilar Development,” BioDrugs, 31, 279–286. DOI: 10.1007/s40259-017-0227-4.
   PubMed Web of Science ®Google Scholar
• Zhang, Y. (2018), “A Comparison of Methods for Estimating Restricted Mean Survival Time,” Master’s thesis, Leiden University.
   Google Scholar